Vimarsana
Biggest News Aggregation in the World

Page 4 - Dan Vahdat News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dan Vahdat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dan Vahdat Today - Breaking & Trending Today

Huma receives 510(k) Class II clearance for its disease-agnostic platform - Vimarsana News

Huma receives 510(k) Class II clearance for its disease-agnostic platform

The FDA clearance comes just three months after the company received EU MDR Class IIb certification for its configurable disease management platform.

Major Companies Issue Complaints Over UK's Worsening Investment Climate - Vimarsana News

Major Companies Issue Complaints Over UK's Worsening Investment Climate

The non-profit think tank Tony Blair Institute for Global Change earlier estimated that the post-Brexit investment levels in Britain are more than 30% lower than the pre- referendum trend.

Britain's post-Brexit policy drift alarms world's executives - Vimarsana News

Britain's post-Brexit policy drift alarms world's executives

The British economy has been the slowest to recover from COVID-19 of all Group of Seven nations and is the only one with a smaller workforce than before the pandemic.

Huma receives multi-condition US FDA 510(k) Class II regulatory clearance for its configurable SaMD disease management p - Vimarsana News

Huma receives multi-condition US FDA 510(k) Class II regulatory clearance for its configurable SaMD disease management p

NEW YORK and LONDON, June 12, 2023 /PRNewswire/ -- Huma Therapeutics ("Huma"), a leading global digital...

HUMA Therapeutics: Huma named for its successful and innovative approach to clinical trials in new UK government review - Vimarsana News

HUMA Therapeutics: Huma named for its successful and innovative approach to clinical trials in new UK government review

Huma's innovative approach to medical research cited in Lord James O'Shaughnessy's review for clinical trials improvement in the UKThe review is part of a new widespread policy approach to ignite